Bayer's Pipeline Is Firing on All Cylinders — the Revenue Race Is a Different Matter
Published on 10/27/2026 at 20:21 | Editorial boerse-global.de
Bayer has spent the week stacking up clinical and regulatory wins. A first-in-class stroke drug cleared in China, a prostate-cancer therapy posting a 58% reduction in metastasis or death, and fresh kidney-disease subanalyses all landed within days of each other. What none of them did was move JPMorgan's numbers: the bank reiterated its "Overweight" rating and 61 euro price target on Monday, a constructive nod that nonetheless stopped short of any upgrade.
That distinction — between a medical advance and a re-rating of the equity — sits at the heart of the investment case. Analyst Richard Vosser welcomed the interim DASL-HiCaP results, but the confirmation of an existing view is not the same as a fresh vote of confidence in future earnings.
Asundexian's China Green Light
The regulatory milestone came with the approval of Asundexian under the brand name Sunharbo, cleared for cutting the risk of recurrent stroke after a non-cardioembolic ischaemic stroke or high-risk TIA. According to Bayer, it is the world's first approved Factor XIa inhibitor. The decision follows an earlier setback, when a trial in atrial fibrillation was halted over insufficient results.
Analysts surveyed by the Frankfurter Allgemeine Zeitung see annual sales of 1–3 billion euros for the drug. Bayer itself speaks of billion-euro revenue without committing to a target of its own, which leaves the size of the eventual contribution firmly in the realm of expectation rather than proven business. The US filing is running under an accelerated review, with a decision possibly due within days, and Bayer plans a US launch before the end of 2026. Some European markets, by contrast, may not see the product for another two to three years.
Should investors sell immediately? Or is it worth buying Bayer?
Nubeqa Delivers Today, Not Tomorrow
Where Asundexian is a promise, Nubeqa is already paying. Second-quarter 2026 sales reached 880 million euros, up 64% year on year, making the drug a key plank in offsetting older products as they fade. The interim analysis of the Phase III DASL-HiCaP trial, run across 1,106 patients, showed Darolutamid plus androgen deprivation therapy and radiotherapy cut the risk of metastasis or death by 58% versus placebo. The four-year metastasis-free survival rate came in at 95% against 88%, in prostate-cancer patients at high risk of recurrence.
Two caveats temper the read-across. Overall survival showed no statistically significant benefit, and severe side effects were more frequent on Darolutamid than in the comparator arm. Nor is the regimen approved yet for the setting studied — a compelling endpoint is not the same as a label expansion, and further regulatory steps remain outstanding.
The Hole Xarelto Is Leaving Behind
The urgency behind all of this shows up in the numbers Bayer is trying to replace. Xarelto revenue fell 42% year on year in the second quarter of 2026 to 374 million euros, squeezed by generic competition, while Eylea faces its own patent cliff. Add the kidney-disease data — subanalyses of the Phase III FIND-CKD trial presented on Thursday, showing consistent effects of Finerenon on proteinuria and kidney-function decline versus placebo in chronic kidney disease patients without diabetes — and the pipeline picture looks broad. It is still a picture of possibilities, not a revenue forecast.
Bayer at a turning point? This analysis reveals what investors need to know now.
Roundup: A Separate Ledger
Off the income statement, the legal overhang remains its own line item. Bloomberg reported that the proposed settlement of up to 7.25 billion US dollars in the Roundup litigation has won preliminary court approval; final sign-off is still pending. Operating progress and legal relief therefore have to be weighed on separate scales — new medicines can strengthen the business, but they do not resolve the litigation.
What November 3 Has to Show
The next hard datapoint arrives on 3 November 2026, when Bayer reports third-quarter results. That release will not validate this week's approval or trial readouts on its own. What it can do is sharpen the economic side of the case — and answer the question investors are really asking. Not whether the pipeline produces medical progress, but whether that progress converts into durable revenue fast enough to cover the patent losses and the remaining financial burdens.
Ad
Bayer Stock: New Analysis - 27 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
